$647 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 80 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BNTC | Exit | BENITEC BIOPHARMA LTDspons adr new | $0 | – | -40,000 | -100.0% | -0.00% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -80,000 | -100.0% | -0.04% | – |
| VTGN | Exit | VISTAGEN THERAPEUTICS INC | $0 | – | -673,628 | -100.0% | -0.07% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -69,200 | -100.0% | -0.07% | – |
| AGLE | Exit | AEGLEA BIOTHERAPEUTICS INC | $0 | – | -187,206 | -100.0% | -0.18% | – |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCads | $0 | – | -107,433 | -100.0% | -0.21% | – |
| MGIC | Exit | MAGIC SOFTWARE ENTERPRISES Lord | $0 | – | -185,288 | -100.0% | -0.23% | – |
| RDWR | Exit | RADWARE LTDord | $0 | – | -102,277 | -100.0% | -0.35% | – |
| AAP | Exit | ADVANCE AUTO PARTS INC | $0 | – | -17,400 | -100.0% | -0.37% | – |
| Exit | INTEC PHARMA LTD JERUSALEM | $0 | – | -620,000 | -100.0% | -0.37% | – | |
| AUTL | Exit | AUTOLUS THERAPEUTICS PLCspon ads | $0 | – | -177,546 | -100.0% | -0.39% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -281,291 | -100.0% | -0.42% | – |
| CAMT | Exit | CAMTEK LTDord | $0 | – | -417,459 | -100.0% | -0.48% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INCcall | $0 | – | -300,000 | -100.0% | -0.53% | – |
| IFF | Exit | INTERNATIONAL FLAVORS&FRAGRA | $0 | – | -30,000 | -100.0% | -0.60% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -95,564 | -100.0% | -0.67% | – |
| TLT | Exit | ISHARES TR20 yr tr bd etf | $0 | – | -45,000 | -100.0% | -0.82% | – |
| XHB | Exit | SPDR SERIES TRUSTs&p homebuild | $0 | – | -166,796 | -100.0% | -0.95% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -140,000 | -100.0% | -0.96% | – |
| MYL | Exit | MYLAN N V | $0 | – | -400,000 | -100.0% | -1.04% | – |
| WVE | Exit | WAVE LIFE SCIENCES LTD | $0 | – | -307,967 | -100.0% | -1.10% | – |
| IFF | Exit | INTERNATIONAL FLAVORS&FRAGRAcall | $0 | – | -63,500 | -100.0% | -1.26% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS IN | $0 | – | -116,000 | -100.0% | -1.26% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -30,000 | -100.0% | -1.28% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -75,000 | -100.0% | -1.30% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -120,000 | -100.0% | -2.49% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDcall | $0 | – | -2,050,000 | -100.0% | -2.59% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -500,000 | -100.0% | -2.74% | – |
| QURE | Exit | UNIQURE NVcall | $0 | – | -265,000 | -100.0% | -2.83% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -770,000 | -100.0% | -4.35% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.